609 related articles for article (PubMed ID: 33186044)
1. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Cannalire R; Cerchia C; Beccari AR; Di Leva FS; Summa V
J Med Chem; 2022 Feb; 65(4):2716-2746. PubMed ID: 33186044
[TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
3. Advances Toward COVID-19 Therapies Special Issue.
Neamati N
J Med Chem; 2022 Feb; 65(4):2713-2715. PubMed ID: 35138859
[No Abstract] [Full Text] [Related]
4. Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review.
Xiao YQ; Long J; Zhang SS; Zhu YY; Gu SX
Bioorg Chem; 2024 Jun; 147():107380. PubMed ID: 38636432
[TBL] [Abstract][Full Text] [Related]
5. Targeting 3CLpro and SARS-CoV-2 RdRp by
Shady NH; Hayallah AM; Mohamed MFA; Ghoneim MM; Chilingaryan G; Al-Sanea MM; Fouad MA; Kamel MS; Abdelmohsen UR
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205768
[TBL] [Abstract][Full Text] [Related]
6. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 M
Citarella A; Scala A; Piperno A; Micale N
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
[TBL] [Abstract][Full Text] [Related]
8. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
9. Discovery of highly potent SARS-CoV-2 M
Chen W; Feng B; Han S; Wang P; Chen W; Zang Y; Li J; Hu Y
Bioorg Med Chem Lett; 2022 Feb; 58():128526. PubMed ID: 34998903
[TBL] [Abstract][Full Text] [Related]
10. Re
Karges J; Kalaj M; Gembicky M; Cohen SM
Angew Chem Int Ed Engl; 2021 May; 60(19):10716-10723. PubMed ID: 33606889
[TBL] [Abstract][Full Text] [Related]
11. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
Diniz LRL; Perez-Castillo Y; Elshabrawy HA; Filho CDSMB; de Sousa DP
Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33430299
[TBL] [Abstract][Full Text] [Related]
12. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.
Alhadrami HA; Sayed AM; Sharif AM; Azhar EI; Rateb ME
Molecules; 2021 May; 26(9):. PubMed ID: 34062737
[TBL] [Abstract][Full Text] [Related]
13. Flavonols as potential antiviral drugs targeting SARS-CoV-2 proteases (3CL
Mouffouk C; Mouffouk S; Mouffouk S; Hambaba L; Haba H
Eur J Pharmacol; 2021 Jan; 891():173759. PubMed ID: 33249077
[TBL] [Abstract][Full Text] [Related]
14. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
Capasso C; Nocentini A; Supuran CT
Expert Opin Ther Pat; 2021 Apr; 31(4):309-324. PubMed ID: 33246378
[TBL] [Abstract][Full Text] [Related]
15.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
16. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
[TBL] [Abstract][Full Text] [Related]
17. Structure-guided design of a perampanel-derived pharmacophore targeting the SARS-CoV-2 main protease.
Deshmukh MG; Ippolito JA; Zhang CH; Stone EA; Reilly RA; Miller SJ; Jorgensen WL; Anderson KS
Structure; 2021 Aug; 29(8):823-833.e5. PubMed ID: 34161756
[TBL] [Abstract][Full Text] [Related]
18. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
Fischer A; Sellner M; Mitusińska K; Bzówka M; Lill MA; Góra A; Smieško M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669738
[TBL] [Abstract][Full Text] [Related]
19. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection.
Dampalla CS; Zheng J; Perera KD; Wong LR; Meyerholz DK; Nguyen HN; Kashipathy MM; Battaile KP; Lovell S; Kim Y; Perlman S; Groutas WC; Chang KO
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34210738
[TBL] [Abstract][Full Text] [Related]
20. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]